CARsgen Therapeutics reports growth in issued share capital

CARsgen Therapeutics Holdings Limited announced an increase in its total number of issued shares, reaching 577,934,314 as of September 30, 2025. This represents a net increase of 1,925,000 shares from the previous month. The company's authorized/registered share capital remained at 200,000,000,000 shares with a total value of $50,000.

The increase in issued shares primarily stemmed from the exercise of share options and the issuance of new shares under various incentive plans. Notably, 9,000 new ordinary shares were issued through the Post-IPO Share Option Scheme, raising HK$207,160. Additionally, 1,916,000 ordinary shares were issued under other agreements, including 4,500 shares from the 2019 Equity Incentive Plan and 1,911,500 shares from the Post-IPO RSU Scheme.

As of September 30, 2025, 2,437,007 shares remain issuable under the pre-IPO 2019 Equity Incentive Plan, and 2,602,590 shares are issuable underlying restricted share units granted under the Post-IPO RSU Scheme.